274 related articles for article (PubMed ID: 28929799)
1. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.
Li W; Sun H; Xu S; Zhu Z; Xu J
Future Med Chem; 2017 Oct; 9(15):1765-1794. PubMed ID: 28929799
[TBL] [Abstract][Full Text] [Related]
2. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.
Wu X; Wang Q; Li W
Anticancer Agents Med Chem; 2016; 16(10):1325-38. PubMed ID: 26899186
[TBL] [Abstract][Full Text] [Related]
5. Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.
Wang J; Miller DD; Li W
Drug Discov Today; 2022 Mar; 27(3):759-776. PubMed ID: 34890803
[TBL] [Abstract][Full Text] [Related]
6. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
7. An overview of tubulin inhibitors that interact with the colchicine binding site.
Lu Y; Chen J; Xiao M; Li W; Miller DD
Pharm Res; 2012 Nov; 29(11):2943-71. PubMed ID: 22814904
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
Coluccia A; Sabbadin D; Brancale A
Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
[TBL] [Abstract][Full Text] [Related]
10. Butterfly Structure: A Privileged Scaffold Targeting Tubulin-Colchicine Binding Site.
Wang Y; Yao Y; Zhu HL; Duan Y
Curr Top Med Chem; 2020; 20(17):1505-1508. PubMed ID: 32543362
[TBL] [Abstract][Full Text] [Related]
11. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
Dong M; Liu F; Zhou H; Zhai S; Yan B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
[TBL] [Abstract][Full Text] [Related]
12. Electrostatic contributions to colchicine binding within tubulin isotypes.
Huzil JT; Barakat K; Tuszynski JA
Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
[TBL] [Abstract][Full Text] [Related]
13. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
14. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
[TBL] [Abstract][Full Text] [Related]
16. An update on the recent advances and discovery of novel tubulin colchicine binding inhibitors.
Weng H; Li J; Zhu H; Carver Wong KF; Zhu Z; Xu J
Future Med Chem; 2023 Jan; 15(1):73-95. PubMed ID: 36756851
[TBL] [Abstract][Full Text] [Related]
17. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.
Tyagi C; Gupta A; Goyal S; Dhanjal J; Grover A
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S3. PubMed ID: 25521775
[TBL] [Abstract][Full Text] [Related]
18. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.
Nguyen TL; McGrath C; Hermone AR; Burnett JC; Zaharevitz DW; Day BW; Wipf P; Hamel E; Gussio R
J Med Chem; 2005 Sep; 48(19):6107-16. PubMed ID: 16162011
[TBL] [Abstract][Full Text] [Related]
19. Discrimination of ligands with different flexibilities resulting from the plasticity of the binding site in tubulin.
Chakraborti S; Chakravarty D; Gupta S; Chatterji BP; Dhar G; Poddar A; Panda D; Chakrabarti P; Ghosh Dastidar S; Bhattacharyya B
Biochemistry; 2012 Sep; 51(36):7138-48. PubMed ID: 22891709
[TBL] [Abstract][Full Text] [Related]
20. Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.
Niu L; Wang Y; Wang C; Wang Y; Jiang X; Ma L; Wu C; Yu Y; Chen Q
Biochem Biophys Res Commun; 2017 Nov; 493(1):718-722. PubMed ID: 28864414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]